26559-Nephew, Kenneth

Kenneth P. Nephew, PhD

Jerry W. and Peggy S. Throgmartin Professor of Oncology

Biology Building 302
Bloomington, IN 47405
Pubmed Logo
Download CV


I have been studying  cancer and epigenetics for nearly three decades.  I have received extramural and  university grants and serve on numerous scientific advisory boards. I  co-lead of the Tumor Microenvironment and Metastasis Program of the IU Simon Comprehensive Cancer Center and serve as the Dean of the Department of Defense Ovarian Cancer Academy. As an IUSM faculty member, I have mentored junior faculty, postdoctoral fellows and have graduated over 20 PhD students.  My long-term goal is to reduce cancer mortality and contribute to a cure for cancer


Key Publications

1.      Wang Y, Zong X, Mitra S, Mitra AK, Matei D, Nephew KP. Interleukin-6 mediates platinum-induced enrichment of ovarian cancer stem cells.  2018 J Clin Invest Insight 3(23). pii: 122360. PMCID: PMC6328027

2.      Zong X, Wang W, Ozes A, Fang FF, Sandusky GE, Nephew KP.  2020  EZH2-mediated Downregulation of the tumor suppressor DAB2IP maintains ovarian cancer stem cells. Cancer Res, 80(20):4371-4385 PMCID: PMC7572866

3.      Matei D, Nephew KP. 2020. Epigenetic Attire in Ovarian Cancer: The Emperor’s New Clothes. invited review, Cancer Research, 80(18): 3775-3785 PMCID: PMC7501210

4.      Wang W, Fang F, Ozes A,  Nephew KP 2021 Targeting ovarian cancer stem cells by dual inhibition of HOTAIR and DNA methylation Mol Cancer Ther, 20(6): 1092-1101I PMCID: PMC8172444

5.      Marino N, German R, Podicheti R,  Rusch DB, Rockey P, Huang J, Sandusky G, Temm CJ,  Althouse S; Nephew KP, Nakshatri H, Liu J, Vode A, Cao S Storniolo A.  2022  Aberrant epigenetic and transcriptional events associated with breast cancer risk. Clin Epigenetics, 14(1):21 PMCID: PMC8830042

6.      Sriramkumar S, Sood R, Huntington TD, Ghobashi AH,  Wang W, Nephew KP, O'Hagan HM. 2022  Platinum-induced mitochondrial OXPHOS contritbutes to cancer stem cell enrichment in ovarian cancer  J Transl Med, 20(1):246 PMCID: PMC9153190

7.      Muralikrishnan V, Fang F, Given TC, Podicheti R, Chtcherbinine M, Metcalfe TX, Sriramkumar S, O'Hagan HM, Hurley TD, Nephew KP.  2022  A novel ALDH1A1 inhibitor blocks platinum-induced senescence and stemness in ovarian cancer. Cancers, 14::3437. PMCID: PMC9318275

8.      Khatpe AS, Dirks R, Bhat-Nakshatri P, Mang H, Batic K, Swiezy S, Olson J, Rao X, Wang Y, Tanaka H, Liu S, Wan J, Chen D, Liu Y, Fang F, Althouse S, Hulsey E, Granatir MM, Addison R, Temm CJ, Sandusky G, Lee-Gosselin A, Nephew K, Miller KD, Nakshatri H. 2023. TONSL is ani mmortalizing oncogene and a therapeutic target in breast cancer. Cancer Res. 2023 83:1345-1360. PMID:37057595

9.      Wang W, Zhou Y, Wang J, Zhang S, Ozes A,  Gao H Fang F, Wang Y, Chu X, Liu Y, Mitra A, O’Hagan H, Nephew KP.  Targeting ovarian cancer stem cells by dual inhibition of the long noncoding RNA HOTAIR and lysine methyltransferase EZH2. under revision bioRxiv 2023.06.26.546524; doi: https://doi.org/10.1101/2023.06.26.546524

10.   Stojanovic L, Rachel Abbotts R, Tripathi K Coon C, Marker R, Liu S, Wan J, Topper MJ, Baylin SB*, Nephew KP*, Feyruz V*. ZNFX1 is a master regulator for epigenetic reprograming of mitochondrial inflammasome signaling and pathogen mimicry in cancer cells.  bioRxiv 2023.02.28.530455; doi:  https://doi.org/10.1101/2023.02.28.530455

Titles & Appointments

  • Jerry W. and Peggy S. Throgmartin Professor of Oncology
  • Professor of Anatomy, Cell Biology & Physiology
  • Adjunct Professor of Obstetrics & Gynecology
  • Adjunct Professor of Biology, College of Arts & Sciences, IU Bloomington
  • Fellow, Indiana Molecular Biology Institute, College of Arts and Sciences, IU Bloomington
  • Education
    1991 PhD The Ohio State University
    1986 MS The Ohio State University
    1983 BS The Ohio State University
  • Research
    1. Cancer epigenetics, epigenetic therapies, ovarian and breast cancers.
    2. Characterizing and targeting ovarian cancer stem cells using epigenetic drugs.
    3. Translational research and clinical trials testing epigenetic therapies against solid tumors (ovarian, breast, germ cell and lung cancers), performing correlative analyses, and testing new hypotheses in the laboratory (bench-bedside-bench).
    4. Identifying the factors that influence long-term survival of ovarian cancer patients and developing therapies and interventions that help patients live longer.
  • Professional Organizations
    American Association for Cancer Research
    American Association for the Advancement of Science
  • Awards
    Org: Graduate and Professional Student Government (GPSG) and University
    Desc: Graduate School Faculty Mentor Award Winner

Looking for patient care?

To schedule an appointment with a faculty member physician of IU School of Medicine, contact Indiana University Health at 888-484-3258 or use the physician finder by clicking the button below.

Find a doctor